Fetuin-A and interleukin-18 levels in ankylosing spondylitis

International Journal of Rheumatic Diseases

Volumn 13, Issue 1, 2010, Pages 75-81

  Sari, Ismail ^a   Kebapcilar, Levent ^a   Taylan, Ali ^b   Bilgir, Oktay ^a   Kozaci, Didem L ^c   Yildiz, Yasar ^a   Yuksel, Arif ^a   Gunay, Necati ^c   Akkoc, Nurullah ^d  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

^b Izmir Tepecik Training and Research Hospital   (Turkey)

^c ADNAN MENDERES UNIVERSITY   (Turkey)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Ankylosing spondylitis; Atherosclerosis; Fetuin A; IL 18

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; FETUIN A; GLUCOSE; INFLIXIMAB; INTERLEUKIN 18; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; REGISTRIES; SPONDYLITIS, ANKYLOSING; TRIGLYCERIDES; TURKEY; UP-REGULATION;

EID: 75649138379     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2009.01448.x     Document Type: Article

References (25)

1. Sari I, Okan T, Akar S. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006, 45:283-6.
2. Sari I, Kebapcilar L, Alacacioglu A. Increased levels of asymmetric dimethylarginine (ADMA) in patients with Ankylosing Spondylitis. Intern Med 2009, 48:1363-8.
3. Caliskan M, Erdogan D, Gullu H. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 2008, 196:306-12.
4. Mathieu S, Joly H, Baron G. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008, 47:1203-7.
5. van Eijk IC, Peters MJ, Serne EH. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009, 68:362-6.
6. Yamagami H, Kitagawa K, Hoshi T. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 2005, 25:1458-62.
7. Blankenberg S, Luc G, Ducimetiere P. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003, 108:2453-9.
8. Blankenberg S, Tiret L, Bickel C. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106:24-30.
9. Rittig K, Thamer C, Haupt A. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis 2009, E-pub ahead of print
10. Weikert C, Stefan N, Schulze MB. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008, 118:2555-62.
11. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-8.
12. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994, 21:1694-8.
13. Calin A, Garrett S, Whitelock H. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-5.
14. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-91.
15. Kishore BK, Gejyo F, Arakawa M. Alpha 2HS-glycoprotein in the serum and urine of patients with renal diseases. Postgrad Med J 1983, 59:304-7.
16. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006, 113:1760-7.
17. Mori K, Emoto M, Araki T. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) 2007, 66:246-50.
18. Kazama JJ. What does the circulating AHSG/fetuin-A level tell us? Clin Exp Nephrol 2007, 11:336-7.
19. Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N, Matsumoto K. Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol 2007, 11:304-8.
20. Sato H, Kazama JJ, Wada Y. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern Med 2007, 46:1685-91.
21. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001, 19:423-74.
22. Zirlik A, Abdullah SM, Gerdes N. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:2043-9.
23. Gracie JA, Forsey RJ, Chan WL. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999, 104:1393-401.
24. Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 2001, 44:1716-7.
25. Tso TK, Huang WN, Huang HY, Chang CK. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006, 45:1148-53.